Use of hormones and risk of venous thromboembolism - Revista Brasileira de Ginecologia e Obstetrícia

Home » Articles » Use of hormones and risk of venous thromboembolism

Febrasgo Position Statement

Use of hormones and risk of venous thromboembolism

Rev Bras Ginecol Obstet. 2024;46:e-FPS02

DOI: 10.61622/rbgo/2024FPS02

Views 228

Key points

•The risk of venous thromboembolism (VTE) is not increased in women using long-acting reversible contraceptive methods (LARCs) with progestogens.

•Oral contraceptives with levonorgestrel or norgestimate confer half the risk of VTE compared to oral contraceptives containing desogestrel, gestodene or drospirenone.

•Progestogen-only pills do not confer an increased risk of VTE.

•Women using transdermal contraceptive patches and combined oral contraceptives (COCs) are at an approximately eight times greater risk of VTE than non-users of hormonal contraceptives (HCs), corresponding to 9.7 events per 10,000 women/years.

•Vaginal rings increase the risk of VTE by 6.5 times compared to not using HC, corresponding to 7.8 events per 10,000 women/years.

•Several studies have demonstrated an increased risk of VTE in transgender individuals receiving hormone therapy (HT).

•Hormone therapy during menopause increases the risk of VTE by approximately two times, and this risk is increased by obesity, thrombophilia, age over 60 years, surgery and immobilization.

•The route of estrogen administration, the dosage and type of progestogen associated with estrogen may affect the risk of VTE in the climacteric.

•Combined estrogen-progesterone therapy increases the risk of VTE compared to estrogen monotherapy.

•Postmenopausal HT increases the risk of thrombosis at atypical sites.

Read Full Text

opener
PDF - English Complete text JATS XML
How to Cite
Mendeley

Search

Search in:

Article type
abstract
book-review
brief-report
case-report
case-report -
correction
editorial
editorial -
letter
letter -
other
other -
rapid-communication
research-article
research-article -
review-article
review-article -
Session
Abstracts of Awarded Papers at the 50th Brazilian Congress of Gynecology and Obstetrics
Authors' Reply
Case Report
Case Report and Treatment
Clinical Consensus Recommendation
Editor's Note
Editorial
Equipments and Methods
Erratum
Febrasgo Position Statement
Letter to the Editor
Methods and Techniques
Original Article
Original Article/Contraception
Original Article/Infertility
Original Article/Obstetrics
Original Article/Oncology
Original Article/Sexual Violence/Pediatric and Adolescent Gynecology
Original Article/Teaching and Training
Previous Note
Review Article
Short Communication
Special Article
Systematic Review
Thesis Abstract
Year / Volume
2024; v.46
2023; v.45
2022; v.44
2021; v.43
2020; v.42
2019; v.41
2018; v.40
2017; v.39
2016; v.38
2015; v.37
2014; v.36
2013; v.35
2012; v.34
2011; v.33
2010; v.32
2009; v.31
2008; v.30
2007; v.29
2006; v.28
2005; v.27
2004; v.26
2003; v.25
2002; v.24
2001; v.23
2000; v.22
1999; v.21
1998; v.20
ISSUE

Comments

Your email address will not be published. Required fields are marked *

Read Full Text

opener
PDF - English Complete text JATS XML
How to Cite
Mendeley

Search

Search in:

Article type
abstract
book-review
brief-report
case-report
case-report -
correction
editorial
editorial -
letter
letter -
other
other -
rapid-communication
research-article
research-article -
review-article
review-article -
Session
Abstracts of Awarded Papers at the 50th Brazilian Congress of Gynecology and Obstetrics
Authors' Reply
Case Report
Case Report and Treatment
Clinical Consensus Recommendation
Editor's Note
Editorial
Equipments and Methods
Erratum
Febrasgo Position Statement
Letter to the Editor
Methods and Techniques
Original Article
Original Article/Contraception
Original Article/Infertility
Original Article/Obstetrics
Original Article/Oncology
Original Article/Sexual Violence/Pediatric and Adolescent Gynecology
Original Article/Teaching and Training
Previous Note
Review Article
Short Communication
Special Article
Systematic Review
Thesis Abstract
Year / Volume
2024; v.46
2023; v.45
2022; v.44
2021; v.43
2020; v.42
2019; v.41
2018; v.40
2017; v.39
2016; v.38
2015; v.37
2014; v.36
2013; v.35
2012; v.34
2011; v.33
2010; v.32
2009; v.31
2008; v.30
2007; v.29
2006; v.28
2005; v.27
2004; v.26
2003; v.25
2002; v.24
2001; v.23
2000; v.22
1999; v.21
1998; v.20
ISSUE

Leia também

close-button

How to cite this article

EndNote RIS

Electronic Document Format (Vancouver)

Barros VIPVL, Oliveira ALML, Nascimento DJ, Zlotnik E, Teruchkin MM, Marques MA, Margarido PFR. Use of hormones and risk of venous thromboembolism. Rev Bras Ginecol Obstet 2024;46:e-FPS02.

Electronic Document Format (ABNT)

Barros, Venina Isabel Poço Viana Leme de; Oliveira, André Luiz Malavasi Longo de; Nascimento, Denis Jose do; Zlotnik, Eduardo; Teruchkin, Marcelo Melzer; Marques, Marcos Arêas; Margarido, Paulo Francisco Ramos. Use of hormones and risk of venous thromboembolism. Rev Bras Ginecol Obstet, v. 46, e-FPS02, Apr. 2024.

Electronic Document Format (APA)

Barros, V. I. P. V. L. , Oliveira, A. L. M. L. , Nascimento, D. J. , Zlotnik, E., Teruchkin, M. M., Marques, M. A., & Margarido, P. F. R. (2024). Use of hormones and risk of venous thromboembolism. Rev Bras Ginecol Obstet, 46, e-FPS02.

Electronic Document Format (ISO)

Barros, Venina Isabel Poço Viana Leme de and Oliveira, André Luiz Malavasi Longo de and Nascimento, Denis Jose do and Zlotnik, Eduardo and Teruchkin, Marcelo Melzer and Marques, Marcos Arêas and Margarido, Paulo Francisco Ramos. Use of hormones and risk of venous thromboembolism. Rev Bras Ginecol Obstet [online]. 2024, vol. 46, [cited 2024-05-12], e-FPS02. Available from: <https://journalrbgo.org/article/use-of-hormones-and-risk-of-venous-thromboembolism/>.
✕

Use of hormones and risk of venous thromboembolism |

Key points

•The risk of venous thromboembolism (VTE) is not increased in women using long-acting reversible contraceptive methods (LARCs) with progestogens. •Oral contraceptives with levonorgestrel or norgestimate confer half the risk of VTE compared to oral contraceptives containing desogestrel, gestodene or drospirenone. •Progestogen-only pills do not confer an increased risk of VTE. •Women using transdermal contraceptive patches and combined oral contraceptives (COCs) are at an approximately eight times greater risk of VTE than non-users of hormonal contraceptives (HCs), corresponding to 9.7 events per 10,000 women/years. •Vaginal rings increase the risk of VTE by 6.5 times compared to not using HC, corresponding to 7.8 events per 10,000 women/years. •Several studies have demonstrated an increased risk of VTE in transgender individuals receiving hormone therapy (HT). •Hormone therapy during menopause increases the risk of VTE by approximately two times, and this risk is increased by obesity, thrombophilia, age over 60 years, surgery and immobilization. •The route of estrogen administration, the dosage and type of progestogen associated with estrogen may affect the risk of VTE in the climacteric. •Combined estrogen-progesterone therapy increases the risk of VTE compared to estrogen monotherapy. •Postmenopausal HT increases the risk of thrombosis at atypical sites.